Quarterly report pursuant to Section 13 or 15(d)

Other current assets (Tables)

v3.24.3
Other current assets (Tables)
9 Months Ended
Sep. 30, 2024
Other current assets  
Summary of other current assets

September 30, 

December 31, 

    

2024

2023

Research and development credits receivable

 

$

24,905

$

46,098

Prepayments

 

14,164

9,954

Clinical materials

 

97

1,329

VAT receivable

1,209

Other current assets

 

3,375

2,412

$

43,750

$

59,793